Qu Biologics Appoints Dr. David Mullins as Chief Scientific Officer

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to 'reboot' the body's immune system to treat cancer and autoimmune disease, announced it has appointed Dr. David Mullins as Chief Scientific Officer.

As the company's Chief Scientific Officer, Dr. Mullins will be responsible for leading the development of the company's Site Specific Immunomodulators and integrating the company's scientific program with its clinical and business development activities. Dr. Mullins, a cancer immunologist, had been serving as a member of Qu Biologics' Scientific Advisory Board before taking on this more active role as the company's Chief Scientific Officer.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "Dr. David Mullins is a recognized leader in cancer immunology and his expertise will be instrumental in the development of our SSI platform and the application of our SSIs in the treatment of various cancers and autoimmune diseases. His guidance as a Scientific Advisor has been invaluable and we are very pleased to welcome David to our leadership team."

Dr. David Mullins stated, "Qu's SSI platform has tremendous potential as a safe and effective immunomodulator, and I'm honored and excited to work with the Qu team on the continued development of SSI technology."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are made of inactivated bacteria aimed at stimulating the body's own immune system against cancer and autoimmune disease. The company's SSI platform represents a promising new approach to cancer and autoimmune disease. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.

About Dr. David Mullins

Dr. Mullins is the Chief Scientific Officer of Qu Biologics and Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth (Hanover, New Hampshire). Dr. Mullins received his PhD in Immunology from Virginia Polytechnic Institute and State University (Virginia Tech), and completed advanced training in tumour immunology at the University of Virginia. Dr. Mullins is a recognized expert in immune cell trafficking to tumours. Through translational research models and collaborative clinical trials, he continues to investigate and develop novel strategies for immune therapy of metastatic cancers. Dr. Mullins is an active member of the Society for the Biological Therapy of Cancer, the American Association for Cancer Research, and the American Association of Immunologists. He frequently serves as a reviewer for leading immunology journals and participates in US National Institutes of Health Grant Review Panels.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company recently launched a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.